Board of Directors
Charles W. Stiefel
Prior to joining Brickell, Charles was chairman and CEO of Stiefel Laboratories, Inc. Founded in 1847, Stiefel Laboratories was a family-owned company for more than 160 years until it was sold to GlaxoSmithKline in 2009. At the time, Stiefel Laboratories was the world's largest privately held pharmaceutical company specializing in dermatological products, with nearly 4,000 employees in more than 30 countries and products distributed in more than 100 countries. Charles first joined the company as general counsel in 1982 and was subsequently named executive vice president and then president. In 2003 Charles was awarded a Lifetime Achievement Award by the South Florida Dermatology Foundation, and in 2006 he was named Ernst & Young's Entrepreneur of the Year in Health Sciences for the state of Florida. Born in Catskill, New York, Charles holds an undergraduate degree from Yale University and a JD degree from Albany Law School.
George B. Abercrombie, R.Ph., MBA
Mr. Abercrombie served as President and Chief Executive Officer at Hoffmann-La Roche Incorporated from 2001-2009 where he was responsible for leading the North American Pharmaceuticals Operations and the Canadian affiliate, Hoffmann-La Roche Ltd. Before joining Roche, Abercrombie was Senior Vice President of U.S. commercial operations at Glaxo Wellcome, with responsibilities encompassing pharmaceutical sales and marketing, electronic commerce, the U.S. managed care system, disease management, business planning and development, and late-stage clinical drug studies. He joined Glaxo as Vice President and General Manager of the Glaxo Pharmaceuticals Division in 1993 following 10 years at Merck, where he held a broad range of positions in sales, marketing, executive sales management and business development. Abercrombie began his career as a pharmacist after receiving a bachelor’s degree in pharmacy from the University of North Carolina at Chapel Hill. He later earned an M.B.A. from Harvard University.
William D. Ju, M.D.
William Ju, M.D. is a board-certified dermatologist and has over 20 years of biopharmaceutical experience in a wide variety of therapeutic areas, including dermatology. He is the President and a Founding Trustee of Advancing Innovation in Dermatology, Inc. Dr. Ju has been President and Chief Executive Officer of Follica, Inc. and Chief Operating Officer at PTC Therapeutics, Inc. In addition, he has held executive positions at Pharmacia Corporation/Pfizer, Inc. Merck & Co., Inc., and Hoffmann La Roche, Inc. in a broad spectrum of product development functions. Dr. Ju served as project leader for SUTENT®, introduced CANCIDAS® into humans, and was part of the product development teams for CRIXIVAN® and TRANSLARNA™. Dr. Ju began his pharmaceutical career at Hoffmann-La Roche where he was a clinical leader for the development of dermatology compounds. Before entering industry, he was a senior staff fellow in basic research in the Laboratory of Cellular Oncology headed by Dr. Douglas Lowy and was affiliated with the Dermatology Branch at the National Cancer Institute, National Institutes of Health. Dr. Ju obtained his M.D. with Alpha Omega Alpha honors at the University of Pennsylvania School of Medicine and his A.B. with Phi Beta Kappa honors at Princeton University.
Mr. Hardy has successfully built an array of pharmaceutical companies. Prior to Brickell, Reginald was the co-founder and President of Concordia Pharmaceuticals, Inc. an oncology drug development company acquired by Kadmon Corporation in 2011. Mr. Hardy was co-founder and President of SANO Corporation, a pharmaceutical company focused on the development of novel transdermal drug delivery systems that was acquired by Elan Corporation. Prior to SANO, Mr. Hardy served as the President of the generics group at IVAX Corporation. Reginald has also held various corporate roles with Hoechst-Roussel Pharmaceuticals, Inc. and Key Pharmaceuticals, Inc. Mr. Hardy earned his B.S. degree in Pharmacy from the University of North Carolina—Chapel Hill and M.B.A. from UNC-Greensboro.
Dennison (Dan) T. Veru
Mr. Veru is a Principal of Palisade Capital and a member of the Investment Policy Committee. Mr. Veru has oversight responsibilities for all the investment strategies at Palisade Capital involving publicly traded securities. From 1992 through 1999, Mr. Veru was the President and Director of Research at Awad Asset Management and helped oversee the firm's growth from start up to more than one billion of small cap institutional and high net worth assets. Prior to Awad, Mr. Veru became associated with the partners of Palisade in 1984 at Drexel Burnham Lambert and later at Smith Barney Harris Upham where he held a variety of analytical roles. In addition to his professional responsibilities, Mr. Veru is a member of the Board of Overseers of the St. Lukes and Roosevelt hospital, a member of the finance committee of the Dwight-Englewood School, and a member of the Board of the McCarton School for autistic children. A graduate of Franklin & Marshall College in 1983, Mr. Veru is a frequent guest on CNBC, Bloomberg News, Fox News and CNN. He also contributes market opinions to various financial publications.
John Doux, M.D.
John Doux has been an analyst at Palo Alto Investors since 2004. He obtained a B.S. with distinction and an M.D. from Stanford University, where he was a Howard Hughes Medical Institute Fellow. He also completed an M.B.A. at the Wharton School of Business where he was a Palmer Scholar. He is board certified in dermatology and maintains an active clinical practice.